<?xml version='1.0' encoding='utf-8'?>
<document id="25336921"><sentence text="Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers."><entity charOffset="80-91" id="DDI-PubMed.25336921.s1.e0" text="cilnidipine" /><entity charOffset="96-105" id="DDI-PubMed.25336921.s1.e1" text="valsartan" /><pair ddi="false" e1="DDI-PubMed.25336921.s1.e0" e2="DDI-PubMed.25336921.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25336921.s1.e0" e2="DDI-PubMed.25336921.s1.e1" /></sentence><sentence text="Although cilnidipine and valsartan are widely coadministered to patients with hypertension, their drug-drug interaction potential has not been investigated"><entity charOffset="9-20" id="DDI-PubMed.25336921.s2.e0" text="cilnidipine" /><entity charOffset="25-34" id="DDI-PubMed.25336921.s2.e1" text="valsartan" /><pair ddi="false" e1="DDI-PubMed.25336921.s2.e0" e2="DDI-PubMed.25336921.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25336921.s2.e0" e2="DDI-PubMed.25336921.s2.e1" /></sentence><sentence text=" This study compared the pharmacokinetic (PK), pharmacodynamic (PD), and tolerability profiles of cilnidipine and valsartan, both alone and in combination, in healthy male subjects"><entity charOffset="98-109" id="DDI-PubMed.25336921.s3.e0" text="cilnidipine" /><entity charOffset="114-123" id="DDI-PubMed.25336921.s3.e1" text="valsartan" /><pair ddi="false" e1="DDI-PubMed.25336921.s3.e0" e2="DDI-PubMed.25336921.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25336921.s3.e0" e2="DDI-PubMed.25336921.s3.e1" /></sentence><sentence text="" /><sentence text="Fifty-four subjects, enrolled into an open-label, single-dose, three-treatment, three-period crossover study, randomly received cilnidipine (10 mg), valsartan (160 mg), or both according to one of six sequences"><entity charOffset="128-139" id="DDI-PubMed.25336921.s5.e0" text="cilnidipine" /><entity charOffset="149-158" id="DDI-PubMed.25336921.s5.e1" text="valsartan" /><pair ddi="false" e1="DDI-PubMed.25336921.s5.e0" e2="DDI-PubMed.25336921.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25336921.s5.e0" e2="DDI-PubMed.25336921.s5.e1" /></sentence><sentence text=" Blood samples were collected at baseline and up to 24 hours after drug administration in each period" /><sentence text=" Plasma concentrations of cilnidipine and valsartan were determined by liquid chromatography with tandem mass spectrometry"><entity charOffset="26-37" id="DDI-PubMed.25336921.s7.e0" text="cilnidipine" /><entity charOffset="42-51" id="DDI-PubMed.25336921.s7.e1" text="valsartan" /><pair ddi="false" e1="DDI-PubMed.25336921.s7.e0" e2="DDI-PubMed.25336921.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25336921.s7.e0" e2="DDI-PubMed.25336921.s7.e1" /></sentence><sentence text=" Maximum plasma concentration (Cmax) and area under the concentration-time curve from 0 to the last measurable time (AUC(last)) were estimated using a noncompartmental method" /><sentence text=" Tolerability was evaluated by assessing adverse events (AEs), vital signs, electrocardiograms, and clinical laboratory tests" /><sentence text=" Blood pressure was also measured for PD assessment" /><sentence text="" /><sentence text="A total of 51 subjects completed the study" /><sentence text=" The PK profile of cilnidipine was not significantly affected by coadministered valsartan; the geometric mean ratio and 90% confidence interval (90% CI) of AUC(last) for cilnidipine with and without valsartan was 1"><entity charOffset="19-30" id="DDI-PubMed.25336921.s13.e0" text="cilnidipine" /><entity charOffset="80-89" id="DDI-PubMed.25336921.s13.e1" text="valsartan" /><entity charOffset="170-181" id="DDI-PubMed.25336921.s13.e2" text="cilnidipine" /><entity charOffset="199-208" id="DDI-PubMed.25336921.s13.e3" text="valsartan" /><pair ddi="false" e1="DDI-PubMed.25336921.s13.e0" e2="DDI-PubMed.25336921.s13.e0" /><pair ddi="false" e1="DDI-PubMed.25336921.s13.e0" e2="DDI-PubMed.25336921.s13.e1" /><pair ddi="false" e1="DDI-PubMed.25336921.s13.e0" e2="DDI-PubMed.25336921.s13.e2" /><pair ddi="false" e1="DDI-PubMed.25336921.s13.e0" e2="DDI-PubMed.25336921.s13.e3" /><pair ddi="false" e1="DDI-PubMed.25336921.s13.e1" e2="DDI-PubMed.25336921.s13.e1" /><pair ddi="false" e1="DDI-PubMed.25336921.s13.e1" e2="DDI-PubMed.25336921.s13.e2" /><pair ddi="false" e1="DDI-PubMed.25336921.s13.e1" e2="DDI-PubMed.25336921.s13.e3" /><pair ddi="false" e1="DDI-PubMed.25336921.s13.e2" e2="DDI-PubMed.25336921.s13.e2" /><pair ddi="false" e1="DDI-PubMed.25336921.s13.e2" e2="DDI-PubMed.25336921.s13.e3" /></sentence><sentence text="04 (0" /><sentence text="98-1" /><sentence text="10)" /><sentence text=" Likewise, cilnidipine did not affect the PK of valsartan; the geometric mean ratio (90% CI) of AUC(last) for valsartan with and without cilnidipine was 0"><entity charOffset="11-22" id="DDI-PubMed.25336921.s17.e0" text="cilnidipine" /><entity charOffset="48-57" id="DDI-PubMed.25336921.s17.e1" text="valsartan" /><entity charOffset="110-119" id="DDI-PubMed.25336921.s17.e2" text="valsartan" /><entity charOffset="137-148" id="DDI-PubMed.25336921.s17.e3" text="cilnidipine" /><pair ddi="false" e1="DDI-PubMed.25336921.s17.e0" e2="DDI-PubMed.25336921.s17.e0" /><pair ddi="false" e1="DDI-PubMed.25336921.s17.e0" e2="DDI-PubMed.25336921.s17.e1" /><pair ddi="false" e1="DDI-PubMed.25336921.s17.e0" e2="DDI-PubMed.25336921.s17.e2" /><pair ddi="false" e1="DDI-PubMed.25336921.s17.e0" e2="DDI-PubMed.25336921.s17.e3" /><pair ddi="false" e1="DDI-PubMed.25336921.s17.e1" e2="DDI-PubMed.25336921.s17.e1" /><pair ddi="false" e1="DDI-PubMed.25336921.s17.e1" e2="DDI-PubMed.25336921.s17.e2" /><pair ddi="false" e1="DDI-PubMed.25336921.s17.e1" e2="DDI-PubMed.25336921.s17.e3" /><pair ddi="false" e1="DDI-PubMed.25336921.s17.e2" e2="DDI-PubMed.25336921.s17.e2" /><pair ddi="false" e1="DDI-PubMed.25336921.s17.e2" e2="DDI-PubMed.25336921.s17.e3" /></sentence><sentence text="94 (0" /><sentence text="83-1" /><sentence text="07)" /><sentence text=" Coadministration of cilnidipine and valsartan reduced blood pressure in an additive way"><entity charOffset="21-32" id="DDI-PubMed.25336921.s21.e0" text="cilnidipine" /><entity charOffset="37-46" id="DDI-PubMed.25336921.s21.e1" text="valsartan" /><pair ddi="false" e1="DDI-PubMed.25336921.s21.e0" e2="DDI-PubMed.25336921.s21.e0" /><pair ddi="false" e1="DDI-PubMed.25336921.s21.e0" e2="DDI-PubMed.25336921.s21.e1" /></sentence><sentence text=" No serious AEs were reported, and both cilnidipine and valsartan were well tolerated"><entity charOffset="40-51" id="DDI-PubMed.25336921.s22.e0" text="cilnidipine" /><entity charOffset="56-65" id="DDI-PubMed.25336921.s22.e1" text="valsartan" /><pair ddi="false" e1="DDI-PubMed.25336921.s22.e0" e2="DDI-PubMed.25336921.s22.e0" /><pair ddi="false" e1="DDI-PubMed.25336921.s22.e0" e2="DDI-PubMed.25336921.s22.e1" /></sentence><sentence text="" /><sentence text="Coadministered cilnidipine and valsartan do not cause a significant PK or PD interaction, and they are well tolerated"><entity charOffset="15-26" id="DDI-PubMed.25336921.s24.e0" text="cilnidipine" /><entity charOffset="31-40" id="DDI-PubMed.25336921.s24.e1" text="valsartan" /><pair ddi="false" e1="DDI-PubMed.25336921.s24.e0" e2="DDI-PubMed.25336921.s24.e0" /><pair ddi="false" e1="DDI-PubMed.25336921.s24.e0" e2="DDI-PubMed.25336921.s24.e1" /></sentence><sentence text="" /></document>